Protagenic Therapeutics, Inc.\new Cash and Restricted Cash
Protagenic Therapeutics, Inc.\new (PTIX) had Cash and Restricted Cash of $565.99 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-19
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $565.99K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.51M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.21M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.72M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $565.99K 10-Q · filed 2026-08-19 |
| 2026-03-31 | $1.51M 10-Q · filed 2026-08-19 |
| 2025-12-31 | $2.21M 10-Q · filed 2026-03-09 |
| 2025-09-30 | $2.72M 10-Q · filed 2025-11-26 |
| 2025-06-30 | $4.10M 10-Q · filed 2026-08-19 |
| 2025-03-31 | $14.53K 10-Q · filed 2026-08-19 |
| 2024-12-31 | $79.57K 10-Q · filed 2026-03-09 |
| 2024-09-30 | $71.40K 10-Q · filed 2025-11-26 |
| 2024-06-30 | $713.63K 10-QT · filed 2025-09-10 |
| 2024-03-31 | $1.63K 10-K · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |